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Abstract
 IMPORTANCE—Outpatient human immunodeficiency virus (HIV) health care facilities 
receive funding from the Ryan White HIV/AIDS Program (RWHAP) to provide medical care and 
essential support services that help patients remain in care and adhere to treatment. Increased 
access to Medicaid and private insurance for HIV-infected persons may provide coverage for 
medical care but not all needed support services and may not supplant the need for RWHAP 
funding.
 OBJECTIVE—To examine differences between RWHAP-funded and non–RWHAP-funded 
facilities and in patient outcomes between the 2 systems.
 DESIGN, SETTING, AND PARTICIPANTS—The study was conducted from June 1, 2009, 
to May 31, 2012, using data from the 2009 and 2011 cycles of the Medical Monitoring Project, a 
national probability sample of 8038 HIV-infected adults receiving medical care at 989 outpatient 
health care facilities providing HIV medical care.
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 MAIN OUTCOMES AND MEASURES—Data were used to compare patient characteristics, 
service needs, and access to services at RWHAP-funded vs non–RWHAP-funded facilities. 
Differences in prescribed antiretroviral treatment and viral suppression were assessed. Data 
analysis was performed between February 2012 and June 2015.
 RESULTS—Overall, 34.4% of facilities received RWHAP funding and 72.8% of patients 
received care at RWHAP-funded facilities. With results reported as percentage (95% CI), patients 
attending RWHAP-funded facilities were more likely to be aged 18 to 29 years (8.5%[7.4%–9.5%] 
vs 5.0%[3.9%–6.2%]), female (29.2%[27.2%–31.2%] vs 20.1%[17.0%–23.1%]), black (47.5% 
[41.5%–53.5%] vs 25.8% [20.6%–31.0%]) or Hispanic (22.5%[16.4%–28.6%] vs 12.9%[10.6%–
15.2%]), have less than a high school education (26.1% [24.0%–28.3%] vs 10.9%[8.7%–13.1%]), 
income at or below the poverty level (53.6%[50.3%–56.9%] vs 23.9%[19.7%–28.0%]), and lack 
health care coverage (25.0%[21.9%–28.1%] vs 6.1% [4.1%–8.0%]). The RWHAP-funded 
facilities were more likely to provide case management (76.1% [69.9%–82.2%] vs 15.4%[10.4%–
20.4%]) as well as mental health (64.0%[57.0%–71.0%] vs 18.0%[14.0%–21.9%]), substance 
abuse (33.6%[27.0%–40.2%] vs 12.0%[8.0%–16.0%]), and other support services; patients 
attending RWHAP-funded facilities were more likely to receive these services. After adjusting for 
patient characteristics, the percentage prescribed ART antiretroviral therapy, reported as adjusted 
prevalence ratio (95% CI), was similar between RWHAP-funded and non–RWHAP-funded 
facilities (1.01 [0.99–1.03]), but among poor patients, those attending RWHAP-funded facilities 
were more likely to be virally suppressed (1.09 [1.02–1.16]).
 CONCLUSIONS AND RELEVANCE—A total of 72.8% of HIV-positive patients received 
care at RWHAP-funded facilities. Many had multiple social determinants of poor health and used 
services at RWHAP-funded facilities associated with improved outcomes. Without facilities 
supported by the RWHAP, these patients may have had reduced access to services elsewhere. Poor 
patients were more likely to achieve viral suppression if they received care at a RWHAP-funded 
facility.
The Ryan White Human Immunodeficiency Virus (HIV)/AIDS Program (RWHAP) was 
established in 1990 to provide funds to states, eligible metropolitan areas, and clinics to 
increase access to high-quality HIV care and treatment for low-income, uninsured, and 
underinsured individuals and families affected by HIV infection.1 An estimated 873 000 
persons were living with a diagnosis of HIV infection in the United States at the end of 
2010.2 The RWHAP reaches more than 500 000 people annually3 and accounts for 16% of 
federal spending on HIV care and treatment.4 Administered by the Health Resources and 
Services Administration, the RWHAP provides funding as a payer of last resort for core 
medical services, including outpatient medical care, medications for the treatment of HIV 
disease, medical case management, and antiretroviral therapy (ART) adherence support. In 
addition, HIV care facilities receive RWHAP funding to provide comprehensive support 
services, including nonmedical case management; assistance with food, housing, and 
transportation; mental health and substance abuse services; and HIV transmission risk 
reduction counseling.
Because many HIV-infected persons lack resources that support health (eg, have incomes 
below the federal poverty level, less than a high school education, and no health care 
coverage),5 provision of support services may improve their health outcomes. Case 
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management; assistance with food, housing, and transportation; and mental health and 
substance abuse services have been associated with increased retention in care6,7; adherence 
counseling has been associated with viral suppression8; and recipients of behavioral risk 
reduction interventions conducted by health educators and counselors were significantly less 
likely to engage in HIV transmission risk behaviors.9 Although the RWHAP has extensive 
data on clients and funded facilities, little is known about how patient characteristics, service 
needs, access to services, and clinical outcomes compare across RWHAP-funded and non–
RWHAP-funded facilities.
Implementation of the Patient Protection and Affordable Care Act10 is expected to expand 
health care coverage for HIV-infected persons. Increased access to Medicaid and private 
insurance will provide coverage for medical care but might not provide coverage for support 
services needed to ensure that patients are able to remain in care and adhere to ART; 
therefore, it is likely that the RWHAP will continue to play a key role in providing these 
crucial services.11 In this changing health care coverage environment, a better understanding 
of the differences in patient needs and services delivered at RWHAP-funded and non–
RWHAP-funded facilities may help inform policy discussions.
We used data from a national probability sample of US outpatient HIV health care facilities 
and patients receiving care at those facilities in 2009 and 2011 to compare the characteristics 
of RWHAP-funded vs non–RWHAP-funded facilities, including (1) types of support 
services provided, (2) sociodemographic and clinical characteristics of patients, and (3) 
likelihood of receipt or unmet need for specific support services. We also compared the 
prevalence of ART prescription and viral suppression among patients at RWHAP-funded vs 
non–RWHAP-funded facilities and assessed whether patients with risk factors for poor 




The Medical Monitoring Project (MMP) is an ongoing, complex-sample, cross-sectional 
survey designed to produce nationally representative estimates of behavioral and clinical 
characteristics of HIV-infected adults receiving medical care in the United States.12,13 As a 
public health surveillance activity, MMP was determined to be nonresearch in accordance 
with the federal human subjects protection regulations at 45 Code of Federal Regulations 
46.101c and 46.102d and in the Centers for Disease Control and Prevention Guidelines for 
Defining Public Health Research and Public Health Non-Research.14,15 Participating states 
or territories and facilities obtained local institutional review board approval to conduct 
MMP, if required locally. All interviewed patients provided informed consent, written or oral 
depending on the local health department requirement. Patients received tokens of 
appreciation with cash value.
For each data collection cycle, US states and territories were sampled first, followed by 
facilities providing HIV care, and finally adults receiving at least 1 medical care visit in 
participating facilities between January 1 and April 30 of the cycle year. All sampled states 
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and territories participated in the MMP (California, Delaware, Florida, Georgia, Illinois, 
Indiana, Michigan, Mississippi, New Jersey, New York, North Carolina, Oregon, 
Pennsylvania, Puerto Rico, Texas, Virginia, and Washington).
Within sampled states and territories, outpatient health care facilities providing HIV medical 
care were sampled with probability proportional to size according to the number of persons 
receiving care for HIV infection. All eligible facilities, defined as those in which providers 
routinely order monitoring CD4+ T-lymphocyte cell count or HIV viral load tests and/or 
prescribe antiretroviral medications, were identified using data from state or local HIV case 
surveillance systems, laboratory testing databases, and other data sources. To ensure that 
patients receiving care at facilities that provided therapy for few HIV patients were 
represented in the patient sample, facilities with low HIV patient volume were linked to 
larger facilities on the facility sampling frame to create linked facility groups with minimum 
patient volumes of 40 to 80, with the threshold varying across project areas. If sampled, all 
participating facilities from the facility group provided separate patient lists for patient 
sampling. The probability of patient selection was then equalized in the patient sampling 
phase and thus resulted in greater representation of facilities with low patient volume in the 
sample than would otherwise occur. Samples of 603 and 570 eligible facilities were selected 
in 2009 and 2011, respectively.
The MMP project area staff collected all facility information via interviews with staff and 
other sources, such as facility webpages, between June 1, 2009, and May 31, 2012. Data 
included facility descriptors (private practice, community health center, hospital affiliated, 
state or local health department, other community-based organization, Veterans 
Administration, and clinical research) that were not mutually exclusive, number of patients 
receiving medical care for HIV infection, facility ownership (public or private), medical and 
support services provided, and funding sources within the past year, including RWHAP 
funding. The MMP project area staff identified whether facilities received funding from any 
RWHAP source, including parts A, B, C, or D.1 If any RWHAP funding was received, a 
facility was considered to be RWHAP-funded. Of the 603 eligible facilities in 2009 and 570 
eligible facilities in 2011, RWHAP funding status was ascertained for 509 (84.4%) and 480 
(84.2%), respectively; a total of 989 facilities were included in this analysis.
Of 603 sampled facilities in 2009 and 570 in 2011, 461 and 473 participated in the patient 
sampling stage of MMP (facility response rate, 76.5% and 83.0%, respectively). Of 9338 
sampled patients at participating facilities in 2009, 4217 had an interview and medical 
record abstraction completed (adjusted patient response rate, 50.7%); of these, 3844 (91.2%) 
received care at facilities for which RWHAP funding status was ascertained. Of 9331 
sampled patients at participating facilities in 2011,4503 individuals had an interview and 
medical record abstraction completed (adjusted patient response rate 48.8%); of whom 4194 
(93.1%) received care at facilities for which RWHAP funding status was ascertained.
Patient data were collected via face-to-face interviews and medical record abstractions for 
8038 individuals between June 1, 2009, and May 31, 2012. Patient information included 
sociodemographic characteristics (age, sex, sexual transmission risk category, race/ethnicity, 
country of birth, educational attainment, income relative to federal poverty level,16 health 
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care coverage, homelessness, and incarceration), substance use behaviors (noninjection and 
injection drug use in the past 12 months, binge alcohol use in the past 30 days), clinical 
factors (time since HIV diagnosis, disease stage, depression, ART prescription, and HIV 
viral suppression), and receipt of and unmet need for medical and support services. Sexual 
transmission risk categories were men who have sex with men whether or not they have sex 
with women, men who have sex with women only, women who have sex with men whether 
or not they have sex with women, and other. Participants who reported no anal, vaginal, or 
oral sex in the past 12 months were categorized according to self-reported sexual orientation. 
Prescription of ART was defined as documentation in the medical record of ART 
prescription in the past 12 months, and viral suppression was defined as documentation in 
the medical record of the most recent viral load being undetectable or less than 200 
copies/mL.
 Statistical Analysis
Facility data were weighted based on known probabilities of selection and adjusted for 
nonresponse using predictors of facility-level response including facility size and university 
affiliation. Patient data were weighted based on known probabilities of selection and 
weighted to adjust for nonresponse using predictors of patient-level response including race/
ethnicity, time since HIV diagnosis, age group, and facility size. The sample design and 
weighting methods allow inference to all outpatient HIV health care facilities and HIV-
infected persons receiving outpatient medical care in the United States between January and 
April in 2009 and 2011.
We estimated proportions of facility and patient characteristics with weighted percentages 
and their corresponding 95% CIs and estimated statistical differences between proportions 
with modified Rao-Scott χ2 tests. We evaluated potential statistical unreliability of 
prevalence estimates with the criterion of a relative SE greater than 30%. To examine 
associations between RWHAP funding status and ART prescription and viral suppression 
among patients, we used multivariable logistic regression with predicted marginal means to 
calculate prevalence ratios (PRs) and 95% CIs. We adjusted associations between RWHAP 
funding status and the outcomes of interest (ART prescription or viral suppression) for 
potential confounding by including variables significantly associated with the outcomes at 
the P < .05 level in the final multivariable models. In addition, we assessed the interaction 
between attending a RWHAP-funded facility and all sociodemographic and clinical factors 
associated with the outcomes to assess whether persons with risk factors for poor outcomes 
(eg, poverty) had similar levels of ART prescription and viral suppression in RWHAP-
funded and non–RWHAP-funded facilities. Interaction terms significant at the P < .05 level 
were included in the final multivariable models.
All analyses accounted for the complex sample design and unequal selection probabilities. 
Analyses were completed using SAS, version 9.3 (SAS Institute Inc), and SAS-callable 
SUDAAN, version 10.0.1 (RTI International).
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We estimate that 34.4% of facilities providing outpatient HIV care to adults in the United 
States received RWHAP funding (Table 1). Compared with non–RWHAP-funded facilities, 
significantly larger proportions of RWHAP-funded facilities cared for more than 400 HIV-
infected patients and were community health centers, state or local health departments, and 
other community-based organizations; larger proportions of non–RWHAP-funded facilities 
cared for less than50 HIV-infected patients and were private practices and Veterans 
Administration facilities. The RWHAP-funded facilities were significantly more likely to 
provide each RWHAP-funded service assessed (Table 2 and eFigure 1 in the Supplement). 
The RWHAP-funded facilities were also significantly more likely to provide general and 
high-risk prenatal care and on-site pharmacy services, which are not funded by the RWHAP. 
Alternative therapies were provided at a similar low prevalence regardless of RWHAP 
funding.
We estimate that 72.8% of US HIV-infected adults who received medical care attended a 
RWHAP-funded facility (Table 3). Persons receiving care at those facilities were more likely 
to be younger, female, black or Hispanic, and born outside the United States. Moreover, 
patients at RWHAP-funded facilities were more likely to have less than a high school 
education, have an income at or below the federal poverty level, have no health care 
coverage, and have been homeless or incarcerated. There were no significant differences in 
injection drug use or binge alcohol use, but patients at non–RWHAP-funded facilities were 
more likely to use any noninjection drugs. Diagnoses were established more recently in 
patients attending RWHAP-funded facilities, and these individuals were more likely to have 
major or other depression. There was no significant difference in ART prescription, but 
patients at RWHAP-funded facilities were less likely to be virally suppressed. Patients who 
received care at RWHAP-funded facilities were significantly more likely to receive all 
services except dental care (Table 4 and eFigure 2 in the Supplement). Patients at RWHAP-
funded facilities were significantly more likely to report unmet needs for dental care and 
assistance with housing, transportation, and food.
In multivariable analysis reported as adjusted PR (Table 5), persons less likely to be 
prescribed ART were aged 18 to 29 and 30 to 39 years compared with those 50 years or 
older (0.85 and 0.94, respectively), were non-Hispanic blacks and persons of other race 
compared with whites (0.97 and 0.94, respectively), and were homeless within the past 12 
months (0.97). Those with less than a high school education were more likely to be 
prescribed ART (1.03). Antiretroviral prescriptions did not differ significantly whether 
patients received care at a facility that received or did not receive RWHAP funding (1.01). 
Females (0.96), non-Hispanic blacks, and persons of other races compared with whites (0.89 
and 0.93, respectively) and those who were homeless (0.89), incarcerated (0.87), or had 
major depression or other depression (0.92 and 0.95, respectively) were less likely to be 
virally suppressed. There were no interactions between attending a RWHAP-funded facility 
and age, sex, race/ethnicity, educational attainment, poverty, homelessness, incarceration, or 
depression that were associated with ART prescription. However, persons at or below the 
poverty level and those aged 30 to 39 years who received care at a RWHAP-funded facility 
compared with those who received care at a non–RWHAP-funded facility (1.09 and 1.17, 
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respectively) were more likely to achieve viral suppression. No interactions between 
attending a RWHAP-funded facility and the other sociodemographic and clinical factors 
assessed were associated with viral suppression.
 Discussion
Outpatient HIV health care facilities funded by the RWHAP provide key medical and 
support services to approximately 75% of HIV-infected adults receiving medical care in the 
United States. Patients receiving care at RWHAP-funded facilities were less likely to have 
resources to support health (eg, were more likely to be less educated, poor, uninsured, 
homeless, and incarcerated), which are factors consistently associated with poor clinical 
outcomes.17 Many patients receiving care at RWHAP-funded facilities used support services 
to secure basic life necessities, with approximately 1 in 3 patients receiving assistance with 
food and transportation and nearly 1 in 5 receiving help obtaining housing.
The RWHAP funds core medical services and support services intended to improve health 
outcomes for low-income, uninsured, and underinsured HIV-infected persons. Facilities 
receiving RWHAP funding were more likely to provide a wide range of on-site support 
services designed to retain patients in care, support ART adherence, and reduce HIV 
transmission risk behaviors; patients at RWHAP-funded facilities were significantly more 
likely to use these services. Despite the greater likelihood of poverty, unstable housing, and 
lack of health care coverage, nearly 75% of patients receiving care at RWHAP-funded 
facilities achieved viral suppression. Although we noted differences in ART prescriptions 
among certain subgroups (eg, age group, race/ethnicity), these was a similar percentage of 
ART prescribing for patients attending RWHAP-funded facilities compared with patients 
attending non–RWHAP-funded facilities. Overall, patients attending RWHAP-funded 
facilities were less likely to achieve viral suppression than were patients attending non–
RWHAP-funded facilities (74.4% vs 79.0%). However, in an analysis adjusting for patient 
characteristics and assessing whether patients with risk factors for poor outcomes (eg, 
poverty) were more likely to attain improved outcomes in RWHAP-funded vs non–
RWHAP-funded facilities, we identified 2 subgroups (persons with incomes at or below the 
poverty level and persons aged 30 to 39 years) who were significantly more likely to achieve 
viral suppression in RWHAP-funded facilities compared with non–RWHAP-funded 
facilities. This finding supports the premise that RWHAP-funded facilities, which provide 
substantial support services for marginalized persons (eg, those living at or below the 
poverty level), provide better care for poor persons compared with non–RWHAP-funded 
facilities. Improved outcomes among persons aged 30 to 39 years attending RWHAP-funded 
facilities compared with those attending non–RWHAP-funded facilities should be explored 
further. Potentially, a substantial percentage of persons aged 30 to 39 years might be 
uninsured, underinsured, and not receiving disability benefits and may benefit preferentially 
from medical and support services provided by the RWHAP, leading to improved retention 
in care and adherence to treatment. Because we had no a priori hypotheses that attendance at 
RWHAP-funded facilities would be more important for one group than another, our 
subgroup findings should be interpreted cautiously and could be spurious.
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Several characteristics of facilities receiving RWHAP funding may optimize HIV-infected 
patient outcomes. A total of 45.4% of RWHAP-funded facilities were community health 
centers and 78.3% of non–RWHAP-funded facilities were private practices. An analysis18 of 
National Ambulatory Medical Care Survey data concluded that federally qualified health 
centers performed as well as or better than private practices on select quality measures. In 
addition, population-based studies19 have demonstrated that patients at RWHAP-funded 
facilities received preventive care of equal or better quality than patients at non–RWHAP-
funded facilities. Moreover, facilities receiving RWHAP funding provide care for larger 
numbers of HIV-infected patients than non–RWHAP-funded facilities, which has been 
associated with better clinical outcomes.20 Finally, the RWHAP model of multidisciplinary 
care has been described21 as an exemplar of the team approach component of the patient-
centered medical home, which is a model for improving how primary care is organized and 
delivered.
Approximately 75% of RWHAP-funded facilities provide on-site case management, which 
facilitates assistance with food, housing, and transportation. Without RWHAP-funded 
facilities, many patients may have limited access to comprehensive on-site support services 
elsewhere, since only 15.4% of non–RWHAP-funded facilities provided case management. 
Mental health and substance abuse disorders are common in the HIV-infected 
population22–24 and are critical barriers to retention in care and adherence to treatment.25 
Patients receiving care at RWHAP-funded facilities were more likely to have access to on-
site mental health and substance abuse services and receive necessary treatment. Patients at 
non–RWHAP-funded facilities needing these services may be more likely to require referral 
for treatment at outside facilities that may be difficult to access, particularly for those with 
Medicaid or no insurance.26 Adherence to ART is essential for viral suppression and 
prevention of the emergence of drug resistance mutations.27,28 Consultations or programs 
specifically designed to support patient adherence to HIV treatment were available at 4 of 5 
RWHAP-funded facilities, and patients receiving care at those facilities were twice as likely 
to receive such services as were patients at non–RWHAP-funded facilities. Without the 
support available at RWHAP-funded facilities, many patients may need to be referred to and 
be willing and able to visit outside facilities for these services.
A variety of evidence-based interventions provided by health educators or counselors in the 
health care setting have resulted in reductions in transmission risk behaviors among 
patients.9 The RWHAP-funded facilities were more likely to provide risk reduction 
counseling sessions by a counselor specifically trained to perform these services and, 
although differences in risk behaviors were not measured, patients receiving care at these 
facilities were more likely to report receiving prevention counseling.
Expansion of health care coverage through implementation of the Patient Protection and 
Affordable Care Act might not fully supplant the need for RWHAP funding to provide 
essential support services, since many of these services are not typically covered by 
Medicaid or private health insurance.11 As the payer of last resort, the RWHAP will fill gaps 
in medical coverage for patients who are newly covered by Medicaid or private insurance. 
Persons receiving care as a result of coverage through the Patient Protection and Affordable 
Care Act and in need of support services not covered by Medicaid or private insurance may 
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be more likely to receive those services if they obtain medical care at RWHAP-funded 
facilities.
Our study was subject to several limitations. First, RWHAP funding status was not 
ascertained for 16% of health care facilities in 2009 or 2011 that were attended by 9% of 
patients in 2009 and 7% of patients in 2011. These facilities and patients were therefore 
excluded from analysis. To assess whether our results were biased by these exclusions, we 
compared facilities and patients with missing data with those without missing data and 
found few significant differences and no significant differences in service provision, receipt 
of services, patient demographics, or viral suppression. Second, not all patients attending 
RWHAP-funded facilities received RWHAP-funded services so our findings should not be 
interpreted as a comparison of patients receiving vs not receiving RWHAP-funded services. 
Finally, although surveys were completed for all eligible sampled facilities, our patient 
response rate was lower than optimal. However, even with low response there is 
considerable value in unbiased sampling from rigorously constructed frames.29 We assessed 
and adjusted for nonresponse using widely accepted statistical techniques, although we 
acknowledge the possibility of residual nonresponse bias. To the extent that persons less 
engaged in care may be less likely to participate in MMP, our findings with regard to levels 
of viral suppression may be affected. However, we have no reason to believe that this bias 
may be different in RWHAP-funded vs non–RWHAP-funded facilities (ie, persons less 
engaged in care maybe less likely to participate regardless of the type of facility), so our 
findings with regard to the comparison of viral load and facility type are unlikely to be 
affected.
 Conclusions
During the present study, 72.8% of HIV-infected patients in the United States received care 
at facilities supported by the RWHAP. These facilities serve patients with multiple social 
determinants of poor health who heavily use on-site services known to be associated with 
improved outcomes. Without health care facilities supported by the RWHAP, these patients 
may have reduced access to support services elsewhere. Despite the challenges they face, 
74.4% of patients at RWHAP-funded facilities achieved viral suppression. After adjusting 
for differences in patient characteristics, patients living in poverty and those aged 30 to 39 
years were more likely to achieve viral suppression if they received care at a RWHAP-
funded facility. The Patient Protection and Affordable Care Act is expected to expand health 
care coverage for HIV-infected persons. Increased access to Medicaid and private insurance 
will provide coverage for medical care but might not provide coverage for all essential 
support services. Therefore, the RWHAP will likely continue to play a role in funding vital 
services key to successful outcomes.
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Table 1
Characteristics of Outpatient HIV Health Care Facilities by Ryan White HIV/AIDS Program Funding Statusa
Characteristic












Facility size (No. of HIV-infected patients)

















































































Abbreviations: HIV, human immunodeficiency virus; RWHAP, Ryan White HIV/AIDS Program.
a
Source of the data was the Medical Monitoring Project, 2009 and 2011.12,13
b
Data presented as number (percentage) are sample size (weighted percentage). Data were weighted based on known probabilities of selection and 
adjusted for nonresponse using predictors of facility-level response. The sample design and weighting methods allow inference to all outpatient 
HIV health care facilities in the United States providing care for patients in the first 4 months of each cycle year (2009–2011).
c
Total of percentages is greater than 100 because categories are not mutually exclusive (ie, facilities could indicate more than 1 descriptor). 
Facilities were not required to have a federally qualified health center designation to indicate that they were a community health center.
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Table 2
Supplemental Services Provided by Outpatient HIV Health Care Facilities in the United States by Ryan White 
HIV/AIDS Program Funding Statusa
Characteristic













































































































Abbreviation: HIV, human immunodeficiency virus; RWHAP, Ryan White HIV/AIDS Program.
a
Source of the data was the Medical Monitoring Project, 2009 and 2011.12,13
b
Data presented as number (percentage) are sample size (weighted percentage). Data were weighted based on known probabilities of selection and 
adjusted for nonresponse using predictors of facility-level response. The sample design and weighting methods allow inference to all outpatient 
HIV health care facilities in the United States providing care for patients in the first 4 months of each cycle year (2009–2011).
c
Consultations or programs specifically designed to improve patient adherence to HIV treatment.
d
Sessions conducted by a counselor trained to conduct this type of counseling.
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Table 3
Characteristics of Patients by Ryan White HIV/AIDS Program Funding Status of Outpatient HIV Health Care 
Facilitya
Characteristic








Total 6013 (72.8) [67.7–77.9] 2025 (27.2) [22.1–32.3]
Age, y
  18–29 596 (7.5) [6.7–8.4] 503 (8.5) [7.4–9.5] 93 (5.0) [3.9–6.2]
<.001
  30–39 1293 (16.7) [15.5–17.9] 1026 (17.9) [16.5–19.3] 267 (13.6) [12.0–15.2]
  40–49 2940 (36.0) [34.6–37.3] 2180 (35.3) [33.7–37.0] 760 (37.8) [35.5–40.1]
  ≥50 3209 (39.8) [38.5–41.1] 2304 (38.3) [36.7–40.0] 905 (43.6) [40.6–46.6]
Sex
  Male 5764 (71.7) [69.7–73.8] 4130 (69.0) [67.0–71.0] 1634 (79.0) [75.9–82.2]
<.001  Female 2152 (26.7) [24.7–28.7] 1782 (29.2) [27.2–31.2] 370 (20.1) [17.0–23.1]
  Transgender 120 (1.5) [1.2–1.9] 99 (1.8) [1.4–2.2] 21 (0.9) [0.5–1.3]
Sexual transmission risk categoryc
  Any MSM 3733 (47.4) [44.0–50.9] 2389 (41.0) [37.5–44.6] 1344 (64.6) [60.3–68.8]
<.001
  MSW only 1980 (23.6) [21.6–25.6] 1703 (27.2) [25.0–29.5] 277 (13.8) [11.8–15.8]
  Any WSM 2100 (26.0) [24.1–27.9] 1736 (28.4) [26.5–30.2] 364 (19.7) [16.7–22.8]
  Other 225 (2.9) [2.4–3.4] 185 (3.3) [2.7–4.0] 40 (1.9) [1.2–2.5]
Race/ethnicity
  White, non-Hispanic 2560 (33.5) [29.4–37.7] 1387 (25.3) [22.2–28.4] 1173 (55.6) [49.6–61.5]
<.001
  Black, non-Hispanic 3316 (41.6) [35.9–47.2] 2831 (47.5) [41.5–53.5] 485 (25.8) [20.6–31.0]
  Hispanic or Latino 1775 (19.9) [15.5–24.2] 1521 (22.5) [16.4–28.6] 254 (12.9) [10.6–15.2]
  Otherd 387 (5.0) [4.2–5.8] 274 (4.8) [3.8–5.7] 113 (5.8) [4.7–6.8]
Born outside the United States 1033 (13.3) [11.6–14.9] 851 (14.7) [12.4–17.0] 182 (9.5) [7.9–11.1] .001
Educational attainment
  <High school 1824 (22.0) [20.1–23.9] 1615 (26.1) [24.0–28.3] 209 (10.9) [8.7–13.1]
<.001  High school diploma or equivalent 2206 (27.2) [25.4–29.0] 1798 (29.5) [27.6–31.4] 408 (21.1) [18.2–24.1]
  >High school 4007 (50.8) [47.8–53.7] 2599 (44.4) [41.7–47.0] 1408 (68.0) [63.5–72.4]
At or below poverty levele,f 3665 (45.4) [42.3–48.5] 3212 (53.6) [50.3–56.9] 453 (23.9) [19.7–28.0] <.001
Health insurance coverage during the past 12 
moe,g
  Continuous 5768 (70.8) [67.9–73.8] 4014 (65.0) [61.8–68.1] 1754 (86.5) [84.1–88.9]
<.001  Lapsed 767 (9.3) [8.4–10.3] 620 (10.0) [8.8–11.2] 147 (7.4) [5.8–9.0]
  None 1480 (19.8) [16.9–22.8] 1358 (25.0) [21.9–28.1] 122 (6.1) [4.1–8.0]
Past 12-mo statuse
  Homeless 716 (8.5) [7.6–9.4] 626 (9.9) [8.7–11.1] 90 (4.8) [3.7–5.9] <.001
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Characteristic








  Incarcerated 428 (5.4) [4.7–6.0] 375 (6.4) [5.6–7.2] 53 (2.7) [1.6–3.8] <.001
  Noninjection drug use 2117 (26.7) [25.1–28.2] 1518 (25.6) [23.9–27.3] 599 (29.6) [27.3–31.9] .003
  Injection drug use 215 (2.5) [1.8–3.2] 172 (2.6) [1.8–3.3] 43 (2.2) [1.3–3.2] .47
Binge alcohol use in the past 30 d 1325 (16.3) [15.4–17.3] 984 (16.1) [14.9–17.3] 341 (16.9) [15.1–18.7] .47
Time since HIV diagnosis, y
  <5 1738 (22.7) [21.5–24.0] 1392 (24.3) [22.7–25.9] 346 (18.6) [16.6–20.6]
<.001  5–9 1772 (21.8) [20.9–22.8] 1350 (22.0) [20.9–23.2] 422 (21.2) [19.2–23.2]
  ≥10 4521 (55.4) [54.0–56.9] 4240 (53.7) [51.8–55.5] 1252 (60.2) [57.6–62.9]
Disease stageh
  AIDS or nadir CD4+ 0–199 cells/µL or CD4+ 
<14%
5555 (68.5) [67.0–70.0] 4240 (69.7) [68.0–71.4] 1315 (65.2) [62.8–67.5]
<.001
  No AIDS and nadir CD4+ 200 to 499 cells/µL or 
CD4+
  14% to <29%
1931 (24.9) [23.6–26.3] 1401 (24.2) [22.7–25.7] 530 (26.8) [24.5–29.1]
  No AIDS and nadir CD4+ ≥500 cells/µL or CD4+ 
≥29%
516 (6.6) [5.9–7.3] 350 (6.1) [5.3–6.8] 166 (8.0) [6.9–9.2]
Depression in the past 2 wk
  Major 873 (11.1) [9.9–12.3] 669 (11.3) [10.0–12.6] 204 (10.5) [8.3–12.8]
.007
  Other 964 (12.7) [11.6–13.7] 769 (13.6) [12.3–14.8] 195 (10.3) [8.7–11.9]
Prescribed ART in the past 12 moe,i 7269 (90.6) [89.5–91.7] 5423 (90.4) [89.1–91.7] 1846 (91.0) [89.4–92.6] .53
Viral suppressionj 3165 (75.5) [73.4–77.6] 2397 (74.4) [72.0–76.8] 768 (79.0) [75.9–82.2] .02
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; MSM, men who have sex with men whether or not they also 
reported sex with women; MSW, men who have sex with women only; RWHAP, Ryan White HIV/AIDS Program; WSM, women who have sex 
with men whether or not they also reported sex with women.
a
Source of the data was the Medical Monitoring Project, 2009 and 2011.12,13
b
Data presented No. (%) are sample size (weighted percentage). Facility and patient data were weighted based on known probabilities of selection 
and adjusted for nonresponse using predictors of facility-level and patient-level response. The sample design and weighting methods allow 
inference to all outpatient HIV health care facilities providing care and HIV-infected persons receiving care in the United States during the first 4 
months of the cycle year (2009 and 2011).
c
Participants who reported no anal, vaginal, or oral sex in the past 12 months were categorized according to self-reported sexual orientation.
d
Includes Asian, American Indian, Alaska native, Native Hawaiian, Other Pacific Islander, and multiracial groups.
e
During the 1-year period preceding the interview (2009 data were collected in interviews conducted between June 2009 and May 2010; 2011 data 
were collected in interviews conducted between June 2011 and May 2012).
f
Determined using the US Department of Health and Human Services poverty guidelines.16
g
Having health insurance or coverage does not include having only RWHAP assistance.
h
AIDS was defined as confirmed HIV infection with either: a CD4+ T-lymphocyte cell count less than 200 cells/µL, a CD4+ T-lymphocyte cell 
percentage of total lymphocytes less than 14%, or a diagnosis of a stage 3–defining opportunistic illness.
i
Documentation in the medical record of prescription of antiretroviral therapy.
j
Documentation in the medical record of the most recent viral load being undetectable or less than 200 copies/mL.
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